Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some ...

About one-third of U.S. adults without diabetes who are eligible for weight loss treatment with glucagon-like peptide 1 (GLP-1) receptor agonists and GLP-1/glucose-dependent insulinotropic polypeptide ...

In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...

While surgery has a low risk for complications, when they do occur, they are serious. This may explain why only 5%-10% of ...

Nearly half of participants in a weight loss program who initiated an antiobesity medication and who consumed alcohol at ...

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...

Defiance ETFs introduces NVOX, a leveraged ETF offering 2X exposure to Novo Nordisk's stock price movements, targeting the ...

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without ...

In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2, subcutaneous semaglutide reduced the ...

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.